Revolutionizing Recovery: Remote Therapeutic Monitoring Reduces Infection-Related Hospital Readmissions in OU Clinical Trial

Patients often face challenges sticking to their IV antibiotic schedules after being discharged from the hospital, leading to frequent readmissions. Community Infusion Solutions, is excited to announce the promising results of a clinical trial for a new therapeutic monitoring device called IV Ensure. The trial, conducted by the University of Oklahoma, demonstrated that IV Ensure significantly reduces infection-related hospital readmissions for patients receiving IV antibiotics at home.

Early results from the trial showed that IV Ensure reduced hospital readmissions by 76% within 30 days and 68% within 90 days after discharge. Patients using IV Ensure had a 94% adherence rate. IV Ensure is a small, non-invasive device that connects to a patient’s IV setup at home. It tracks medication infusions and sends real-time data to case managers who monitor progress. If you need help, the device even has “happy” and “sad” buttons to request a call.

“Hospital readmissions are a major challenge for health systems, especially for patients on IV antibiotics at home,” said Joseph Sassine, M.D., principal investigator of the trial and an infectious diseases physician at OU Health and assistant professor in the OU College of Medicine. “IV Ensure allows us to monitor patients’ adherence to their medication regimens, ensuring they receive the care they need to recover fully.”

“Patients could be managed remotely from Dallas to Oregon to the Mississippi Delta and positively impact readmission rates among some of the most challenging chronic diseases,” said Mitchell Berenson, president and CEO of Community Infusion Solutions and developer of IV Ensure.

IV Ensure is approved by the U.S. Food and Drug Administration and is covered by Medicare, making it accessible to a wide range of patients.

Read more from The University of Oklahoma about the impact of IV Ensure.

Revolutionizing Recovery: Remote Therapeutic Monitoring Reduces Infection-Related Hospital Readmissions in OU Clinical Trial